ADMA BIOLOGICS, INC. 10-Q filing
Filed 2026-05-06 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001140361-26-019336
- Form type
- 10-Q
- CIK
- 0001368514
- Primary document
- https://www.sec.gov/Archives/edgar/data/1368514/000114036126019336/ef20070429_10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ADMA BIOLOGICS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $114.5M | - | - |
| Cost Of Revenue | $33.7M | - | - |
| Gross Profit | $80.8M | - | - |
| Operating Income | $58.3M | - | - |
| Net Income | $45.3M | - | - |
| Eps Basic | 0.19 | - | - |
| Eps Diluted | 0.19 | - | - |
| Cash And Equivalents | $138.2M | - | - |
| Total Assets | $665.2M | - | - |
| Total Liabilities | $274.9M | - | - |
| Shareholders Equity | $390.3M | - | - |
| Operating Cash Flow | $58.2M | - | - |
| Capital Expenditures | $2.5M | - | - |